Relvar Ellipta (fluticasone furoate vilanterol trifenatate): Reviews and patient testimonials

Relvar Ellipta 184 micrograms/22 micrograms inhalation powder, pre-dispensed

Asthma

Relvar Ellipta is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta₂-agonist and inhaled corticosteroid) is appropriate:

• patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta₂-agonists.

• patients already adequately controlled on both inhaled corticosteroid and long-acting beta₂-agonist.

Relvar Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed

Asthma

Relvar Ellipta is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta₂-agonist and inhaled corticosteroid) is appropriate:

• patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta₂-agonists.

• patients already adequately controlled on both inhaled corticosteroid and long-acting beta₂-agonist.

COPD (Chronic Obstructive Pulmonary Disease)

Relvar Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV₁<70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy.